RE:RE:RE:News Out!PL summarizes it well.... “We are pleased to see that PBI-4050 continues to deliver the same solid results in patients with metabolic syndrome and type 2 diabetes, but what is perhaps even more interesting is the meaningful reduction in biomarkers which when elevated are associated with cardiovascular and kidney complications”, commented Mr. Pierre Laurin, CEO of ProMetic. “This provides us with very valuable confirmation of efficacy in important parameters ahead of our upcoming placebo controlled clinical trials”, added Mr. Laurin. foof